PAMELA FLAVIN-LEE: Open Payments
NPI 1093244204 · WILLIAMSBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,219 in 60 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $901 · 2025 $1,219
Food & beverage: $1,142Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $366 |
| Janssen Biotech, Inc. | 12 | $250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $109 |
| Sumitomo Pharma America, Inc. | 4 | $104 |
| Celltrion USA Inc. | 5 | $92 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Ardelyx, Inc. | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 2 | $44 |
| Gilead Sciences, Inc. | 2 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
Products named: TREMFYA, SKYRIZI, GEMTESA, VEGZELMA, ENTYVIO, DUPIXENT, IBSRELA, RINVOQ.
Industry payments across VA — which companies pay providers there.
